FY2020 EPS Estimates for Inspire Medical Systems Decreased by Analyst (NASDAQ:INSP)

Share on StockTwits

Inspire Medical Systems (NASDAQ:INSP) – Equities researchers at Svb Leerink reduced their FY2020 EPS estimates for shares of Inspire Medical Systems in a research note issued on Wednesday, July 10th. Svb Leerink analyst R. Newitter now forecasts that the company will post earnings of ($1.53) per share for the year, down from their previous forecast of ($1.29). Svb Leerink also issued estimates for Inspire Medical Systems’ FY2021 earnings at ($1.19) EPS.

Inspire Medical Systems (NASDAQ:INSP) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.04. The company had revenue of $16.30 million for the quarter, compared to analysts’ expectations of $17.79 million. The company’s quarterly revenue was up 63.0% on a year-over-year basis.

Several other research firms have also commented on INSP. Zacks Investment Research upgraded shares of Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Saturday. Bank of America restated a “sell” rating on shares of Deutsche Bank in a report on Monday, July 8th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $57.20.

NASDAQ INSP opened at $67.15 on Friday. Inspire Medical Systems has a one year low of $35.43 and a one year high of $69.71. The firm has a 50 day simple moving average of $58.68.

Institutional investors and hedge funds have recently bought and sold shares of the company. FinTrust Capital Advisors LLC purchased a new stake in shares of Inspire Medical Systems during the first quarter valued at approximately $34,000. Capital Financial Planning LLC purchased a new stake in shares of Inspire Medical Systems during the fourth quarter valued at approximately $27,000. Marshall Wace North America L.P. purchased a new stake in shares of Inspire Medical Systems during the first quarter valued at approximately $45,000. Advisory Services Network LLC raised its stake in shares of Inspire Medical Systems by 273.3% during the first quarter. Advisory Services Network LLC now owns 1,120 shares of the company’s stock valued at $64,000 after purchasing an additional 820 shares during the period. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of Inspire Medical Systems during the fourth quarter valued at approximately $50,000.

In other news, Director Joyce Erony sold 191,192 shares of Inspire Medical Systems stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $66.98, for a total transaction of $12,806,040.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Richard Buchholz sold 4,000 shares of Inspire Medical Systems stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $50.05, for a total transaction of $200,200.00. The disclosure for this sale can be found here. Insiders sold 473,266 shares of company stock worth $28,674,342 in the last 90 days.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Further Reading: Correction

Earnings History and Estimates for Inspire Medical Systems (NASDAQ:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply